BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Damiris K, Tafesh ZH, Pyrsopoulos N. Efficacy and safety of anti-hepatic fibrosis drugs. World J Gastroenterol 2020; 26(41): 6304-6321 [PMID: 33244194 DOI: 10.3748/wjg.v26.i41.6304] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Yu S, Ji G, Zhang L. The role of p53 in liver fibrosis. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1057829] [Reference Citation Analysis]
2 Wang Y, Wu C, Zhou J, Fang H, Wang J. Overexpression of estrogen receptor β inhibits cellular functions of human hepatic stellate cells and promotes the anti-fibrosis effect of calycosin via inhibiting STAT3 phosphorylation. BMC Pharmacol Toxicol 2022;23:77. [PMID: 36207725 DOI: 10.1186/s40360-022-00617-y] [Reference Citation Analysis]
3 Niu X, Meng Y, Wang Y, Li G. Established new compound IMB16-4 self-emulsifying drug delivery systems for increasing oral bioavailability and enhancing anti-hepatic fibrosis effect. Biomed Pharmacother 2022;154:113657. [PMID: 36942601 DOI: 10.1016/j.biopha.2022.113657] [Reference Citation Analysis]
4 Chen H, Huang J, Ko C, Sainaghi PP. Peach Kernel Extracts Inhibit Lipopolysaccharide-Induced Activation of HSC-T6 Hepatic Stellate Cells. International Journal of Clinical Practice 2022;2022:1-6. [DOI: 10.1155/2022/4869973] [Reference Citation Analysis]
5 Chen M, Wu Z, Du Z, Sun S, Wu J, Luo J. Diagnostic accuracy of red blood cell distribution width to platelet ratio for predicting liver fibrosis in patients with chronic hepatitis B: A meta-analysis. Gastroenterología y Hepatología (English Edition) 2022;45:361-372. [DOI: 10.1016/j.gastre.2021.10.003] [Reference Citation Analysis]
6 Ghandian S, Thapa R, Garikipati A, Barnes G, Green‐saxena A, Calvert J, Mao Q, Das R. Machine learning to predict progression of non‐alcoholic fatty liver to non‐alcoholic steatohepatitis or fibrosis. JGH Open. [DOI: 10.1002/jgh3.12716] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Hu Q, Liu M, You Y, Zhou G, Chen Y, Yuan H, Xie L, Han S, Zhu K. Dual inhibition of reactive oxygen species and spleen tyrosine kinase as a therapeutic strategy in liver fibrosis. Free Radic Biol Med 2021;175:193-205. [PMID: 34492311 DOI: 10.1016/j.freeradbiomed.2021.08.241] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Yin K, Li X, Luo X, Sha Y, Gong P, Gu J, Tan R. Hepatoprotective Effect and Potential Mechanism of Aqueous Extract from Phyllanthus emblica on Carbon-Tetrachloride-Induced Liver Fibrosis in Rats. Evid Based Complement Alternat Med 2021;2021:5345821. [PMID: 34712342 DOI: 10.1155/2021/5345821] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
9 Chen M, Wu Z, Du Z, Sun S, Wu J, Luo J. Diagnostic Accuracy of Red Blood Cell Distribution Width to Platelet Ratio for Predicting Liver Fibrosis in Patients with Chronic Hepatitis B: A Meta-analysis. Gastroenterol Hepatol 2021:S0210-5705(21)00303-4. [PMID: 34757161 DOI: 10.1016/j.gastrohep.2021.10.001] [Reference Citation Analysis]
10 Sánchez PS, Rigual MDM, Djouder N. Inflammatory and Non-Inflammatory Mechanisms Controlling Cirrhosis Development. Cancers (Basel) 2021;13:5045. [PMID: 34680192 DOI: 10.3390/cancers13205045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Niu X, Wang X, Niu B, Meng Y, He H, Wang Y, Li G. Costunolide Loaded in pH-Responsive Mesoporous Silica Nanoparticles for Increased Stability and an Enhanced Anti-Fibrotic Effect. Pharmaceuticals (Basel) 2021;14:951. [PMID: 34681175 DOI: 10.3390/ph14100951] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Ahrari A, Najafzadehvarzi H, Taravati A, Tohidi F. The inhibitory effect of PLGA-encapsulated berberine on hepatotoxicity and α-smooth muscle actin (α-SMA) gene expression. Life Sci 2021;284:119884. [PMID: 34389401 DOI: 10.1016/j.lfs.2021.119884] [Reference Citation Analysis]
13 Khanam A, Saleeb PG, Kottilil S. Pathophysiology and Treatment Options for Hepatic Fibrosis: Can It Be Completely Cured? Cells 2021;10:1097. [PMID: 34064375 DOI: 10.3390/cells10051097] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
14 Xue Y, Zhang M, Li T, Liu F, Zhang LX, Fan XP, Yang BH, Wang L. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss. World J Gastroenterol 2021; 27(14): 1497-1506 [PMID: 33911470 DOI: 10.3748/wjg.v27.i14.1497] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Niu X, Wang X, Niu B, Li G, Yang X, Wang Y, Li G. Novel IMB16-4 Compound Loaded into Silica Nanoparticles Exhibits Enhanced Oral Bioavailability and Increased Anti-Liver Fibrosis In Vitro. Molecules 2021;26:1545. [PMID: 33799909 DOI: 10.3390/molecules26061545] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]